Hypertensive heart disease & left ventricular hypertrophy
End-organ cardiac damage · Cardiac
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Chronic hypertension causes left ventricular hypertrophy, diastolic dysfunction and ultimately heart failure, atrial fibrillation and increased sudden-death risk. Regression of hypertrophy with blood-pressure control improves outcomes.
Red flags
- New heart failure symptoms
- Syncope (consider arrhythmia or outflow obstruction)
- Atrial fibrillation with rapid rates
- Chest pain suggesting ischaemia
- Very high LV mass with features suggesting an alternative cardiomyopathy
Assessment
Differential diagnosis
- Hypertensive LVH
- Hypertrophic cardiomyopathy
- Aortic stenosis LVH
- Infiltrative cardiomyopathy (amyloid)
- Athlete's heart
- HFpEF of other cause
Investigations
- ECG (LVH voltage criteria, strain pattern)
- Echocardiogram (wall thickness, LV mass, diastolic function)
- Cardiac MRI to clarify aetiology if uncertain
- Ambulatory BP monitoring
- Renal function and urine ACR
- NT-proBNP if heart failure suspected
Management
- Confirm LVH on echo/ECG and relate it to blood-pressure history
- Exclude mimics such as HCM, amyloid and aortic stenosis
- Assess diastolic function and screen for heart failure with preserved EF
- Pursue strict blood-pressure control to promote hypertrophy regression
- Favour RAAS blockade (ACEi/ARB), which best regresses LV mass
- Add a calcium blocker or thiazide-like diuretic to reach target
- Screen for and manage atrial fibrillation
- Manage HFpEF symptoms with diuretics for congestion and an SGLT2 inhibitor
- Treat concurrent coronary disease and risk factors aggressively
- Reinforce lifestyle: salt reduction, weight loss, exercise, alcohol limits
- Monitor LV mass regression over time
- Arrange cardiology follow-up if heart failure or arrhythmia develops
Drugs & doses
Ramipril 2.5-10 mg PO OD (or candesartan 8-32 mg OD) — best for LVH regression
Amlodipine 5-10 mg PO OD
Indapamide 1.5-2.5 mg PO OD
Dapagliflozin 10 mg PO OD if HFpEF present
Spironolactone 25-50 mg PO OD for resistant hypertension
Disposition
GP-led hypertension optimisation with regression monitoring; cardiology referral for heart failure, arrhythmia or diagnostic uncertainty.
Complications & pitfalls
- Heart failure (preserved then reduced EF)
- Atrial fibrillation
- Sudden cardiac death
- Myocardial ischaemia
- Stroke
Exam pearls
- ACEi/ARB therapy produces the greatest regression of LV mass for a given BP reduction
- Regression of LVH independently improves cardiovascular outcomes
- Distinguish hypertensive LVH from HCM and amyloid, which change management
- LVH is a potent risk marker for AF and sudden death
- Strain pattern on ECG reflects more advanced hypertrophic remodelling
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.